Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cancer genetic immunotherapy].

S Paul1, E Regulier, R Etienne

  • 1Transgène S.A., laboratoire d'immunologie clinique et expérimentale, 2, rue Adolphe-Hirn, 67082 cedex, Strasbourg, France. paul@transgene.fr

Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine
|January 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost of a Pulmonary Arterial Hypertension-Related Hospitalization in Belgium.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

16p11.2 Locus modulates response to satiety before the onset of obesity.

International journal of obesity (2005)·2015
Same author

Bronchial tuberculosis in a pulmonary tuberculosis patient; exercise of the lesion; healing.

Revue de la tuberculose·2010
Same author

Exclusion of NFYB as candidate gene for congenital splay leg in piglets and radiation hybrid mapping of further five homologous porcine genes from human chromosome 12 (HSA12).

Cytogenetic and genome research·2007
Same author

The use of MapPop1.0 for choosing a QTL mapping sample from an advanced backcross population.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2007
Same author

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
Same journal

Catastrophic CD34+ autologous hematopoietic stem cell collection despite sustained mobilization and solutions to rescue the harvests.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Title of the study: Corrected Count Increment as a Predictor of Early Graft Dysfunction and Mortality Following Living Donor Liver Transplantation.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

TLR4/MD-2 complex promotes transfusion-related acute lung injury pathogenesis through the activation of the AP-1 and NF-κB signaling pathways.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

The Strategic Utility of Cryopreserved Platelets in Outer Space.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Genotyping of Human Neutrophil Antigen-3 by High Resolution Melting Analysis in Southern Thai Blood Donors.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Transfusion rate and risk factors in hemiarthroplasty of hip: A nationwide cohort study.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
See all related articles

Cancer immunotherapy has advanced, but recombinant IL-2 and IFN-alpha remain key for renal carcinoma, melanoma, and lymphoma. Newer approaches like vaccination and gene therapy show limited efficacy for solid tumors.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Context:

  • Cancer immunotherapy has seen significant advancements in the last decade.
  • Recombinant Interleukin-2 (IL-2) and Interferon-alpha (IFN-alpha) are established treatments for renal carcinoma, melanoma, and lymphoma.
  • Current immunotherapeutic strategies like vaccination, gene therapy, and cellular therapy have not yet achieved sufficient clinical efficacy against solid tumors.

Purpose:

  • To review and summarize the diverse range of cancer immunotherapy approaches currently under development.
  • To provide an overview of specific strategies, including antigenic vaccination.
  • To discuss non-specific approaches, such as the in-situ transfer of immuno-stimulating genes into tumor sites.

Summary:

  • The review details various cancer immunotherapy strategies, highlighting the continued importance of recombinant IL-2 and IFN-alpha for specific cancers.

Related Experiment Videos

  • It examines antigenic vaccination as a targeted immunotherapy approach.
  • Non-specific methods, including gene transfer for immuno-stimulation at the tumor site, are also discussed.

    • Impact:

    • Provides a comprehensive overview of the current landscape of cancer immunotherapy.
    • Identifies the limitations of emerging immunotherapies for solid tumors.
    • Offers insights into established and experimental therapeutic avenues for cancer treatment.